Table 4.
Predicted incidence of disease and Expected Costs: Results over a 5-Year Period for 1,000 Patients*
| Higher-Risk Scenario (Olanzapine) | Baseline Value | Lower-Risk Scenario (Ziprasidone) | |
|---|---|---|---|
| Event incidence | |||
| Myocardial infarction | 9 | 8 | 8 |
| Death from coronary heart disease | 1 | 1 | 1 |
| Angina pectoris | 9 | 8 | 7 |
| Coronary insufficiency | 1 | 0 | 0 |
| Diabetes | 102 | 64 | 58 |
| Costs (in 2011 U.S. dollars) | |||
| Myocardial infarction | $444,135 | $408,686 | $372,817 |
| Death from coronary heart disease | $14,068 | $12,947 | $11,813 |
| Angina pectoris | $50,819 | $46,769 | $42,669 |
| Coronary insufficiency | $9,250 | $8,513 | $7,767 |
| Diabetes | $1,043,653 | $652,465 | $587,254 |
| Total | $1,561,925 | $1,129,380 | $1,022,320 |
*
Results are reported for 1,000 patients with chronic schizophrenia. Costs are from the perspective of Medicaid. Baseline scenario shows incidence and costs predicted for the population before administration of the higher-risk or lower-risk antipsychotic agent.